0620/24SCR019-18/R10
Media Highlights
From the 2024 ASCO® Annual Meeting
2
Media Outlet Article / Coverage
American Journal of Managed
Care
ADC Improvements Mean More Targets, New Questions
About Sequencing
Becker's Hospital Review 'Smart Warheads' Of Cancer: Experts' Excitement for
Treatment Approach Grows
Healthbook Dr Erika Hamilton Summarizes the DESTINY-Breast03 Trial
which She Also Presented at ASCO 2024
(Scroll to "Breast Cancer")
Nature Medicine Trastuzumab Deruxtecan versus Trastuzumab Emtansine in
HER2-Positive Metastatic Breast Cancer: Long-Term Survival
Analysis of The DESTINY-Breast03 Trial
NBCNews.com Cancer Fighting Antibodies Inject Chemo Directly into Tumor
Sales, Upping Effectiveness
OncLive Second-Line T-DXd Data Remain Strong in HER2+ Metastatic
Breast Cancer
Oncology Learning Network Trastuzumab Deruxtecan Remains Superior to Trastuzumab
Emtansine Among Patients With HER2-Positive Metastatic
Breast Cancer
Targeted Oncology RxPONDER: Use of AMH Levels in Premenopausal Women
Targeted Oncology Recent Updates from the postMONARCH Study
Targeted Oncology INAVO120: Inavolisib Combination Therapy in PIK3CA-Mutated
Breast Cancer
Targeted Oncology Key Updates from DESTINY-Breast06
Targeted Oncology Recent Data from JBCRG-M06/EMERALD in HER2+ Breast
Cancer
Erika Hamilton, MD
SCRI
Continued ➔
